STOCKHOLM and LA JOLLA, Calif., March 23, 2016 /PRNewswire/ -- IRRAS AB, a commercial stage medical technology company pioneering breakthrough devices to meet the challenges of fluid control and management for a broad range of CNS therapeutic applications and procedures, today announced the appointment of Anders P. Wiklund to its Board of Directors. The majority shareholders of IRRAS have endorsed Mr. Wiklund's board membership, which will be formalized at the company's upcoming shareholder meeting in April. Mr. Wiklund, a pharmacist by training, is an accomplished industry leader with expertise in operations, strategy, corporate development, and fund raising in both the United States and Europe. Among other appointments Mr. Wiklund was President & CEO of KabiVitrum Inc., KabiPharmacia Inc., President of Pharmacia Development Corp and co-founder of Esperion Therapeutics.
"Anders brings to IRRAS a rare combination of corporate development expertise, proven business acumen, and international executive leadership demonstrated over four decades," said Kleanthis G. Xanthopoulos, Ph.D., Executive Chairman and acting CEO of IRRAS. "We look forward to his contributions as we implement our clinical, commercial and operational goals to establish IRRAS as a leading medical device company."
"I am very pleased to be joining the Board of IRRAS," commented Mr. Wiklund. "IRRAS is an attractive company with high potential, innovative first-in-class devices like IRRAflowTM, passionate team members and an evolving product strategy with global market opportunities. IRRAS is positioned for the next stage of development and I am excited about contributing to its future."
Mr. Wiklund has accumulated a wealth of operational, business development, and strategic advisory experience from his long-standing career in the biotechnology and pharmaceutical industries in Europe and the United States. Most notably, Mr. Wiklund spent 29 years with the Kabi and Pharmacia group of companies, where he held a number of executive level positions, such as Managing Director of KabiVitrum in the UK, President of KabiVitrum International in Sweden, President and CEO of KabiVitrum and KabiPharmacia in the United States. Mr. Wiklund also currently serves on the boards of EffRx Pharmaceuticals SA, where he is Chairman, Life Medical AB and Inspirion Delivery Technologies. Mr. Wiklund holds a Master of Pharmacy from the Pharmaceutical Institute, Stockholm, Sweden and studied business administration at the University of Stockholm.
Mr. Wiklund joins Kleanthis G. Xanthopoulos, Ph.D., Executive Chairman and acting CEO of IRRAS, Christos Panotopoulos, M.D., Ph.D., Chief Medical Officer of IRRAS, Saeid Esmaeilzadeh, Ph.D., CEO of Serendipity Innovations and founder of several innovative life sciences, medical technology and clean technology companies, and Marios Fotiadis, M.B.A., CEO of the Vandel Group.
IRRAS AB is a commercial stage medical technology company formed to develop and commercialize breakthrough devices for a broad range of brain pathology therapeutic applications and procedures. IRRAS was founded in 2012 by a leading neurosurgeon with the goal to introduce innovative devices for brain surgery. IRRAflow™ is the company's flagship commercial medical device that provides intelligent, dynamic control of CNS fluids. The company's products are protected by key intellectual property patents and patent applications. With its unique product development expertise, qualified investors and globally recognized board and clinical advisors, IRRAS is well-positioned to improve patient outcomes and establish a leadership position in the medical device market. IRRAS is operational in Germany and San Diego, USA with corporate headquarters in Stockholm, Sweden. For more information, please visit www.irras.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/irras-ab-appoints-anders-p-wiklund-to-its-board-of-directors-300240156.html
SOURCE IRRAS AB